Private Placements, Capital Formation,
Restructuring & Recapitalizations



Pure Bioscience ~ $6,500,000 Common Stock ~ March 2006

PURE Biosciences patented new antimicrobial molecule, silver dihydrogen citrate (SDC), is stabilized ionic silver that can serve as a platform for a broad range of products in various markets. The Company is pursuing near-term revenue opportunities for its first commercialized SDC-based product, Axen30, a powerful hard surface disinfectant, while developing large mid- and long-term revenue opportunities in active ingredient and pharmaceutical products. Taglich Brothers was pleased to provide the Company the financial resources needed to significantly accelerate their business strategy.

The information contained herein does not constitute a solicitation of any order to buy or sell any securities. The information provided herein may be displayed and printed for your personal, noncommercial use only. You may not reproduce, retransmit, distribute, disseminate, sell, publish, broadcast or circulate the information to anyone, without the express written consent of Taglich Brothers, Inc.